PRESS RELEASE

innate pharma

THREE POSTERS ON THE ANTI-KIR PROGRAM TO BE PRESENTED AT THE UPCOMING ASH ANNUAL MEETING

Marseille, November 12, 2013

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, announces today that three posters on the anti-KIR program will be presented at the upcoming 55th ASH Annual Meeting (December 7-10, 2013) in New Orleans, LA.

Two of these posters present data from clinical studies with IPH2101, the hybridoma version of the anti-KIR antibody lirilumab: an extension of the Phase I trial in Acute Myeloid Leukemia and a Phase I trial testing IPH2101 combined with lenalidomide in relapsed Multiple Myeloma. The third poster presents preclinical data demonstrating enhanced efficacy of a cytotoxic antibody when combined with an anti-KIR antibody.

- **"Repeated Dosing Of Anti-KIR (IPH2101) As Maintenance Therapy In Ederly Patients With Acute Myeloid Leukemia"**
  Session Name: 615. Acute Myeloid Leukemia: Therapy, excluding Transplantation: Poster II
  Date: Sunday, December 8, 2013
  Presentation Time: 6:30 PM - 8:30 PM
  Location: Ernest N. Morial Convention Center, Hall E

- **"A Phase I Trial Of Anti-KIR Monoclonal Antibody IPH2101 and Lenalidomide For Multiple Myeloma"**
  Session Name: 653. Myeloma: Therapy, excluding Transplantation: Poster II
  Date: Sunday, December 8, 2013
  Presentation Time: 6:30 PM - 8:30 PM
  Location: Ernest N. Morial Convention Center, Hall G

- **"Anti-KIR Antibody Enhancement Of Anti-Lymphoma Activity Of Natural Killer Cells As Monotherapy and In Combination With Anti-CD20 Antibodies"**
  Session Name: 625. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents: Poster III
  Date: Monday, December 9, 2013
  Presentation Time: 6:00 PM - 8:00 PM
  Location: Ernest N. Morial Convention Center, Hall G

Posters will be available at their public presentation on Innate Pharma's website.



About Innate Pharma:

Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drug candidates for cancer and inflammatory diseases.

The Company specializes in the development of novel monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its innovative approaches have led to licensing agreements with Novo Nordisk A/S and Bristol-Myers Squibb.

Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate Pharma is based in Marseilles, France, and had 84 employees as at September 30, 2013.

Learn more about Innate Pharma at www.innate-pharma.com.

Practical Information about Innate Pharma shares:

ISIN code	FR0010331421
Ticker code	IPH

Disclaimer:

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the *Document de Reference* prospectus filed with the AMF, which is available on the AMF website (http://www.amf-france.org) or on Innate Pharma's website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Innate Pharma
Laure-Hélène Mercier
Director, Investor Relations
Phone: +33 (0)4 30 30 30 87
investors@innate-pharma.com

ATCG Press
Marielle Bricman

Mob.: +33 (0)6 26 94 18 53
mb@atcg-partners.com